Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds Companies want ‘orphan’ drugs kept out of ‘most-favored nation’ pilots

https://www.statnews.com/2026/08/05/cms-drug-pricing-pilot-programs-rare-disease-drugs/ By John WilkersonAug. 5, 2026 Washington Correspondent